Precision Medicine in Neurodegenerative Disorders: Part II Volume 193

• Gebundenes Buch

Produktbeschreibung

Precision Medicine in Neurodegenerative Disorders, Part Two, Volume 193  in the Handbook of Clinical Neurology deals with the "How" in the reconfiguration of our approach to slow accelerated brain aging. The book rethinks  animal models on which therapies are tested, outlines the progress and expected changes in biological subtyping efforts using lysosomal, endosomal, mitochondrial, immune dysregulation, and inflammatory mechanisms of disease pathophysiology, and the growing role of microbiome in shaping disease. The volume separates the potentially disease-modifying neurorescue and neurorestoration, (e.g., gene therapy and cell replacement therapy) from true precision "medicine"¿matching biology with the mechanism of intervention of interest. Specific chapters are dedicated to the promise and challenges of extracellular vesicles for both diagnosis and treatment, the growing application of digital measures and other evaluations of clinical response, the nuts and bolts of novel adaptive clinical trial designs, and the regulatory changes needed to facilitate drug development for disease-modification purposes.

Produktdetails

• Handbook of Clinical Neurology Nr.193
• Verlag: Elsevier Health Sciences
• Seitenzahl: 392
• Erscheinungstermin: 5. Juli 2023
• Englisch
• ISBN-13: 9780323855556
• ISBN-10: 0323855555
• Artikelnr.: 66135685

Inhaltsangabe

Part 3 Basic Science Development 1. Role of rodent models in advancing
precision medicine for Parkinson disease 2. The allure and pitfalls of the
prion-like aggregation in neurodegeneration 3. The shift to a proteinopenia
paradigm in neurodegeneration 4. Disease mechanisms as subtypes: Lysosomal
dysfunction in the endolysosomal Parkinson disease subtype 5. Disease
mechanisms as subtypes: Mitochondrial and bioenergetic dysfunction 6.
Disease mechanisms as subtypes: Immune dysfunction in Parkinson disease 7.
Disease mechanisms as subtypes: Inflammation in Parkinson disease and
related disorders 8. Disease mechanisms as subtypes: Microbiome 9. LRRK2:
Genetic mechanisms vs genetic subtypes 10. Genetic mechanism vs genetic
subtypes: The example of GBA 11. Subtyping monogenic disorders: Huntington
disease
Part 4 Clinical Trials and Therapeutic Approaches 12. Disease-modifying vs
symptomatic treatments: splitting over lumping 13. Restorative cell and
gene therapies for Parkinson disease 14. The promise and challenges of
extracellular vesicles in the diagnosis of neurodegenerative diseases 15.
Therapeutic potential of extracellular vesicles in neurodegenerative
disorders 16. Lessons from antiamyloid-ß immunotherapies in Alzheimer
disease 17. Lessons from immunotherapies in multiple sclerosis 18. Adaptive
clinical trials and master protocols 19. Role of novel endpoints and
evaluations of response in Parkinson Disease 20. Leveraging the regulatory
framework to facilitate drug development in Parkinson disease